A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year [CNBC]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: CNBC
Now, analysts say the French biotech could be bought by a larger peer for as much $23 billion. “Abivax ticks all the boxes for a strategic acquisition,” Stifel analyst Damien Choplain told CNBC. In this article Europe's best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax , the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn's disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 index's second-best performing stock, mining company Fresnillo , which rose 453%. Now, the big question for analysts seems to be when, not if, Abivax announces a deal. The stock, listed in 2015, largely ranged between 10 and 20 euros but it wasn't until 10 years later that it really took off Shares surged 510% in a day after Abivax reported the results of a late-stage trial for an ulcerative colitis medicine in July, beating eve
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- AstraZeneca (NASDAQ:AZN) had its "sell" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- What Makes AstraZeneca (AZN) a Strong Growing Company? [Yahoo! Finance]Yahoo! Finance
- AstraZeneca Spotlights 2025 Growth, 2026 Launch Wave and $80B 2030 Goal at JPM Conference [Yahoo! Finance]Yahoo! Finance
- Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note [Yahoo! Finance]Yahoo! Finance
- JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 1/8/26 - Form 6-K
- 1/2/26 - Form 6-K
- 12/22/25 - Form 6-K
- AZN's page on the SEC website